Posted by Michael Wonder on 18 Jan 2018
Aspyrian Therapeutics announces successful advances in RM-1929 clinical development in recurrent head and neck cancer, including fast track designation granted by the FDA
16 January 2018 - Aspyrian plans to initiate pivotal clinical trials for RM-1929 in the first quarter of 2018.
Aspyrian Therapeutics today announced that the U.S. FDA has granted fast track designation for RM-1929, a first-in-class precision targeted therapy, for treatment of patients with loco-regional recurrent head and neck squamous cell carcinoma that have failed 2 lines of therapies.
RM-1929 is currently being tested in an ongoing Phase 2 study in recurrent head and neck cancer (Study RM-1929/101, NCT02422979). Enrolment has been completed and Aspyrian expects to report top-line data in the second half of 2018.
